Belatacept-Based Immunosuppression in De Novo Liver Transplant Recipients: 1-Year Experience From a Phase II Randomized Study
Open Access
- 17 July 2014
- journal article
- research article
- Published by Elsevier in American Journal of Transplantation
- Vol. 14 (8) , 1817-1827
Abstract
No abstract availableKeywords
Funding Information
- Bristol-Myers Squibb
- ClinicalTrials.gov (NCT00555321)
This publication has 27 references indexed in Scilit:
- Belatacept: from rational design to clinical applicationTransplant International, 2011
- Kidney Transplantation After Previous Liver Transplantation: Analysis of the Organ Procurement Transplant Network DatabaseTransplantation, 2011
- Liver antigen-presenting cellsJournal of Hepatology, 2011
- An Integrated Safety Profile Analysis of Belatacept in Kidney Transplant RecipientsTransplantation, 2010
- Survival Benefit After Liver Transplantation: A Single European Center ExperienceTransplantation, 2009
- Management of renal dysfunction in the liver transplant recipientCurrent Opinion in Organ Transplantation, 2009
- Chronic Renal Failure after Transplantation of a Nonrenal OrganNew England Journal of Medicine, 2003
- Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: Results from a double-blind randomized placebo-controlled trialLiver Transplantation, 2002
- A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipientsLiver Transplantation, 2001
- Histological grading and staging of chronic hepatitisJournal of Hepatology, 1995